Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: China Internet Weekly (6Mar2023): JD and more

In today’s briefing:

  • China Internet Weekly (6Mar2023): JD, Kuaishou, Baidu, Weibo, Vipshop
  • Taiwan Tech Weekly: HP Says No Major PC Recovery in 2023E; Signs of Display ICs Early Turn-Around?
  • [Bilibili Inc. (BILI US) Target Price Change]: Minor Protection Would Be a Pending Issue
  • [Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter
  • Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers
  • Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth
  • IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers
  • Valero Energy: Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)
  • Diageo: A Rare Gift From Mr. Market
  • Enterprise Product Partners: Major Drivers

China Internet Weekly (6Mar2023): JD, Kuaishou, Baidu, Weibo, Vipshop

By Ming Lu

  • Two JD.com departments began to try fresh food front-line warehouse again.
  • Radio and Television Administration plans to clean the content in short video.
  • Herman Yu, Baidu’s chief strategy officer and formerly CFO, just resigned.

Taiwan Tech Weekly: HP Says No Major PC Recovery in 2023E; Signs of Display ICs Early Turn-Around?

By Vincent Fernando, CFA

  • Hon Hai reports YoY increase in January + February sales, maintains outlook.
  • Hewlett Packard results: CEO says does not expect significant PC recovery in FY2023E. Fitipower results show display ICs potentially bottoming earlier than most segments.
  • Memory Monitor: Two latest signals indicate lower margins and extended high inventories; biased Long Micron vs. Short Nanya Tech.

[Bilibili Inc. (BILI US) Target Price Change]: Minor Protection Would Be a Pending Issue

By Shawn Yang

  • BILI’s 4Q22 top line was basically in line, while non-GAAP net loss beat cons. by 8.28%. We largely dial down 2023 revenue forecast. 
  • Moreover, we also suggest that recent meeting by the National Radio and Television Administration (NRTA) to curb short video addiction for minor protection would heavily impact BILI.
  • Maintain SELL and cut TP to US$ 15.4, which implies 1.85X PS in 2023.

[Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter

By Shawn Yang

  • Luckin Coffee reported its 4Q22 revenue, non-GAAP operating income, and non-GAAP net income (9.1%), (11.4%), (57.9%) lower than our estimate. 
  • The store temporary close due to Covid impact is the main reason for revenue miss, and the higher income tax payment is the reason for the miss on NI.  
  • We expect Luckin to catch up the store expansion schedule in 1Q23 at 730 new stores, and reach to 10,500 total stores by the end of 2023. 

Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers

By Oshadhi Kumarasiri

  • South Korea’s largest e-commerce company, Coupang (CPNG US) sank around 20% leading up to 4Q22 earnings. It dropped another 9% soon after the earnings report to around $14.0 per ADS.
  • Meanwhile, the valuation remains expensive compared to regional peers as Coupang is trading at an 80% premium to the second most expensive e-commerce name in the region.
  • If the share price breaks the trend line here, we think shares could go on to fall below the last year’s bottom of $8.98 per ADS.

Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth

By Tina Banerjee

  • Global Health (Medanta) (MEDANTA IN) reported double-digit growth in revenue, EBITDA, and net profit during Q3 and 9MFY23, driven by increasing footfalls, rising ARPOB, and faster-than-expected ramp-up of new hospitals.
  • The company plans to add 1,000–1,500 beds in next 2–3 years, with ~70% of the planned bed addition being at existing hospitals, thereby entailing lower capex per bed.
  • Recently, Medanta has announced a new asset light partnership to launch a 300-bed hospital in Indore under operations and management arrangement. The hospital is expected to commence operation in FY27.  

IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers

By Baptista Research

  • IDEXX had a strong finish to the year, reflected in the company’s all-around beat in the last quarter.
  • Its revenues increased organically, driven by organic gains in CAG Diagnostic and strong growth in its water and software businesses.
  • Organic revenue growth in the quarter was supported by solid organic growth across its major business segments and growth in diagnostic imaging and veterinary software revenues.

Valero Energy: Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)

By Baptista Research

  • Valero had a solid year-end, with refineries running at 97% of their capacity in a positive refining margin situation.
  • Besides, significantly discounted sour crude oils and fuel oils helped its refinery.
  • High natural gas costs in Europe also encouraged refiners to process sweet crude oils rather than sour crude oils, placing additional pressure on sour crude oils.

Diageo: A Rare Gift From Mr. Market

By Vladimir Dimitrov, CFA

  • Diageo’s share price has been underperforming for far too long due to outside factors that have little to do with the business itself.
  • The premium brand portfolio in combination with the well-executed acquisition strategy creates a unique opportunity.
  • The company is well-positioned to retain and even improve its industry-leading margins.

Enterprise Product Partners: Major Drivers

By Baptista Research

  • Enterprise Product Partners delivered a mixed set of results in the quarter.
  • Enterprise moved a record 11.2 million barrels of oil equivalent per day which helped it deliver an all-around beat.
  • They believe that a wide gas-to-crude differential could result in a considerable cost advantage for American petrochemicals globally.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars